PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies

Clinical Oncology

Volumn 28, Issue 5, 2016, Pages 317-326

  Paleari, L ^a,b   Puntoni, M ^a   Clavarezza, M ^a   DeCensi, M ^a   Cuzick, J ^c   DeCensi, A ^a,c,d  

^a GALLIERA HOSPITAL   (Italy)

^b Public Health Agency   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Adjuvant trials; Aspirin; Colorectal cancer; Overall survival; PIK3CA; Post diagnosis use

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; GENE; GENE MUTATION; HAZARD RATIO; HUMAN; META ANALYSIS; METASTASIS INHIBITION; OVERALL SURVIVAL; PIK3CA GENE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; COLORECTAL NEOPLASMS; EPIDEMIOLOGY; GENETICS; MORTALITY; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLORECTAL NEOPLASMS; EPIDEMIOLOGIC STUDIES; HUMANS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 84950112625     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2015.11.008     Document Type: Article

References (53)

1. Rothwell P.M., Wilson M., Elvin C.E., et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomized trials. Lancet 2010, 376(9754):1741-1750.
2. Rothwell P.M., Wilson M., Price J.F., et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012, 379:1591-1601.
3. Rothwell P.M., Fowkes F.G., Belch J.F., et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377(9759):31-41.
4. Liao X., Lochhead P., Nishihara R., et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012, 25(367):1596-1606.
5. Chae Y.K., Kunwha K., David S.H., et al. PIK3CA mutation, aspirin use and mortality in patients with metastatic colorectal cancer participating in early-phase clinical trials. Cancer Res 2013, 73(Suppl. 1, abstract 164).
6. Domingo E., Church D.N., Sieber O., et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol 2013, 31:4297-4305.
7. Kothari N., Kim R., Jorissen R.N., et al. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncol 2015, 54(4):487-492.
8. Reimers M.S., Bastiaannet E., Langley R.E., et al. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med 2014, 174(5):732-739.
9. Labelle M., Hynes R.O. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov 2012, 2:1091-1099.
10. Palumbo J.S., Talmage K.E., Massari J.V., et al. Platelets and fibrin(ogen) increase metastatic potential by implementing natural killer cell-mediated elimination of tumor cells. Blood 2005, 105:178-185.
11. Erpenbeck L., Schon M.P. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 2010, 115:3227-3236.
12. Gay L.J., Felding-Habermann B. Contribution of platelets to tumor metastasis. Nat Rev Cancer 2011, 11:123-134.
13. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
14. Aleksandrova K., Jenab M., Bueno-de-Mesquita H.B., et al. Biomarker patterns of inflammatory and metabolic pathways are associated with risk of colorectal cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Eur J Epidemiol 2014, 29:261-275.
15. Tsilidis K.K., Branchini C., Guallar E., et al. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J cancer 2008, 123(5):1133-1140.
16. Wang D., Dubois R.N. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010, 29(6):781-788.
17. Eberhart C.E., Coffey R.J., Radhika A., et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107(4):1183-1188.
18. Ogino S., Kirkner G.J., Nosho K., et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 2008, 14(24):8221-8227.
19. Vogel L.K., Saebo M., Hoyer H., et al. Intestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and colorectal carcinogenesis. Plos One 2014, 9(8):1-8.
20. Samuels Y., Wang Z., Bardelli A., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304(5670):554.
21. Kaur J., Sanyal S.N. PI3-kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac. Tumour Biol 2010, 31(6):623-631.
22. Uddin S., Ahmed M., Hussain A., et al. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer 2010, 126(2):382-394.
23. Di Popolo A., Memoli A., Apicella A., et al. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 2000, 19(48):5517-5524.
24. Stroup D.F., Berlin J.A., Morton S.C. Meta-analysis of observational studies in epidemiology. A proposal for reporting. JAMA 2000, 283:2008-2012.
25. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. J Clin Epidemiol 2009, 62:1006-1012.
26. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
27. Sterne J.A., Sutton A.J., Ioannidis J.P., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. Br Med J 22 Jul, 2011, 343:d4002.
28. Cuzick J., Thorat M.A., Bosetti C., et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 2015, 26(1):47-57.
29. Dubè C., Rostom A., Lewin G., US Preventive Services Task Force, et al. The use of aspirin for primary prevention of colorectal cancer. A systematic review prepared for the US Preventive Services Task Force. Ann Intern Med 2007, 146(5):365-375.
30. Algra A.M., Rothwell P.M. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomized trials. Lancet Oncol 2012, 13:518-527.
31. Bosetti C., Rosato V., Gallus S., Cuzick J., La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012, 23(6):1403-1415.
32. Thun M.J., Jacobs E.J., Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012, 9:259-267.
33. Langley R.E., Burdett S., Tierney J.F., et al. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?. Br J Cancer 2011, 105(8):1107-1113.
34. Langley R.E., Rothwell P.M. Potential biomarker for aspirin use in colorectal cancer therapy. Nat Rev Clin Oncol 2013, 10(1):8-10.
35. Smith T., Elwood P., Keating C., et al. The Aspirin Foundation Scientific Conference: the history, the present state and the future of aspirin prophylaxis. Ecancermedicalscience 2014, 8:388.
36. Ruffin M.T.I.V., Krishnan K., Rock C.L., et al. Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst 1997, 89:1152-1160.
37. Sample D., Wargovich M., Fisher S.M., et al. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev 2002, 11:275-279.
38. Bosman F.T. WHO classification of tumours of the digestive system 2010, World Health Organization, International Agency for Research on Cancer, Lyon. 4th ed.
39. Perez V.B., Romera L.A., Hernandez P.S., et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer 2012, 12:260.
40. Lia X., Morikawa T., Lochhead P., et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012, 18(8):2257-2268.
41. Yamauchi M., Morikawa T., Kuchiba A., et al. Assessment of colorectal cancer molecularfeatures along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012, 61:847-854.
42. Rosty C., Young J.P., Walsh M.D., et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. Plos One 2013, 8(6):1-9.
43. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49(6):1374-1403.
44. McCleary N.J., Dotan E., Browner I. Refining the chemotherapy approach for older patients with colon cancer. J Clin Oncol 2014, 32(24):2570-2580.
45. Bastiaannet E., Sampieri K., Dekkers O.M., et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 2012, 106:1564-1570.
46. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
47. Jessup J.M., Stewart A., Greene F.L., et al. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005, 294:2703-2711.
48. Sargent D.J., Goldberg R.M., Jacobson S.D., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 345:1091-1097.
49. de Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11(8):753-762.
50. Yang Z.-Y., Wu X.-Y., Huang Y.-F., et al. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. Int J Cancer 2013, 133(8):1914-1925.
51. Ali R., Toh H.C., Chia W.K. ASCOLT Trial Investigators. The utility of aspirin in Dukes C and high risk Dukes B colorectal cancer - the ASCOLT study: study protocol for a randomized controlled trial. Trials 2011, 12:261.
52. http://www.addaspirintrial.org/.
53. Phillips I., Langley R., Gilbert D., et al. Aspirin as a treatment for cancer. Clin Oncol 2013, 25(6):333-335.